Brendan Tinsley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brendan Tinsley has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Kimberly Mulligan
Department of Biological Sciences, California State University, Sacramento, 6000 J Street, Sacramento, CA 95819, USA
2 shared publications - A. Ceballos
Department of Biological Sciences, California State University, Sacramento, 6000 J Street, Sacramento, CA, 95819, United States
1 shared publication A. Penn
Department of Biological Sciences, California State University, Sacramento, 6000 J Street, Sacramento, CA, 95819, United States
1 shared publicationAdam Alfareh
Department of Biological Sciences, California State University, Sacramento, 6000 J Street, Sacramento, CA, 95819-6077, USA
1 shared publication- Adam S. Adler
Program in Epithelial Biology and Cancer Biology Program, Stanford University School of Medicine, Stanford, California 94305, USA
1 shared publication Alexandra Davis
Department of Biological Sciences, California State University, Sacramento, 6000 J Street, Sacramento, CA, 95819-6077, USA
1 shared publication
Latest Publications
- Open Access
- 15 January 2022
- Published by Elsevier in NeuroToxicology
- Vol. 89, 67-78
Bisphenol a affects neurodevelopmental gene expression, cognitive function, and neuromuscular synaptic morphology in Drosophila melanogaster
- 15 January 2022
- Published by Elsevier in NeuroToxicology
- Vol. 89, 67-78
Open AccessBisphenol a affects neurodevelopmental gene expression, cognitive function, and neuromuscular synaptic morphology in Drosophila melanogaster
- 15 April 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (8) , 989-999
Generation of recombinant hyperimmune globulins from diverse B-cell repertoires
Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin, have multiple drawbacks, including low potency, impurities, insufficient supply and batch-to-batch variation. Here we describe a microfluidics and molecular genomics strategy for capturing diverse mammalian antibody repertoires to create recombinant multivalent hyperimmune globulins. Our method generates of diverse mixtures of thousands of recombinant antibodies, enriched for specificity and activity against therapeutic targets. Each hyperimmune globulin product comprised thousands to tens of thousands of antibodies derived from convalescent or vaccinated human donors or from immunized mice. Using this approach, we generated hyperimmune globulins with potent neutralizing activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in under 3 months, Fc-engineered hyperimmune globulins specific for Zika virus that lacked antibody-dependent enhancement of disease, and hyperimmune globulins specific for lung pathogens present in patients with primary immune deficiency. To address the limitations of rabbit-derived anti-thymocyte globulin, we generated a recombinant human version and demonstrated its efficacy in mice against graft-versus-host disease.
- 15 April 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (8) , 989-999
Generation of recombinant hyperimmune globulins from diverse B-cell repertoires
Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin, have multiple drawbacks, including low potency, impurities, insufficient supply and batch-to-batch variation. Here we describe a microfluidics and molecular genomics strategy for capturing diverse mammalian antibody repertoires to create recombinant multivalent hyperimmune globulins. Our method generates of diverse mixtures of thousands of recombinant antibodies, enriched for specificity and activity against therapeutic targets. Each hyperimmune globulin product comprised thousands to tens of thousands of antibodies derived from convalescent or vaccinated human donors or from immunized mice. Using this approach, we generated hyperimmune globulins with potent neutralizing activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in under 3 months, Fc-engineered hyperimmune globulins specific for Zika virus that lacked antibody-dependent enhancement of disease, and hyperimmune globulins specific for lung pathogens present in patients with primary immune deficiency. To address the limitations of rabbit-derived anti-thymocyte globulin, we generated a recombinant human version and demonstrated its efficacy in mice against graft-versus-host disease.
- Open Access
- 1 January 2021
- Published by Elsevier in NeuroToxicology
- Vol. 82, 146-157
Exposure to bisphenol A differentially impacts neurodevelopment and behavior in Drosophila melanogaster from distinct genetic backgrounds
- 1 January 2021
- Published by Elsevier in NeuroToxicology
- Vol. 82, 146-157
Open AccessExposure to bisphenol A differentially impacts neurodevelopment and behavior in Drosophila melanogaster from distinct genetic backgrounds